K-ras LSL-G12D ; p53 Fl/Fl or p53 LSL-R270H/Fl or p53 Viral cre-dependent expression of K-ras G12D and p53 mutant variants: both p53 alleles deleted vs. one deleted and one with R270H mutation or one with R172H mutation.
Adenocarcinoma spectrum with accelerated tumor progression; tumors of higher grades and more invasive compared to K-ras G12D alone tumors; metastasis to thoracic LNs and kidney; dominant negative effect conferred by p53 R270H allele.
p53 somatic mutations identified in ~10%-35% of human lung adenocarcinoma. GEMM used to study tumor progression and therapeutics; for example, NFKB inhibition or combined CDK1 and PARP inhibition.
K-ras LSL-G12D ; Lkb1 Fl/Fl or Lkb1 Fl/-Viral cre-dependent expression of K-ras G12D and inactivation of Lkb1.
Adenocarcinoma spectrum with accelerated tumor progression compared to K-ras G12D alone tumors; more than half of adeno-cre-treated K-ras;Lkb1 Fl/ or K-ras;Lkb1 Fl/-mice harbored squamous cell carcinomas (SCC) or adenosquamous carcinomas, and 2 of 27 lungs showed large cell carcinomas; metastasis to regional LNs and axial skeleton.
Lkb1 somatic mutations identified in 8%-26% of human lung carcinoma and occur in adenocarcinoma and SCC. Integrative genomic and proteomic profiles of this GEMM revealed SRC activation and synergistic tumor regression by combined SRC, PI3K, and MEK1/2 inhibition. K-ras LSL-G12D ; p16 Ink4a-/-or Ink4a/Arf -/-Viral cre-dependent expression of K-ras G12D and p16 Ink4a or Ink4a/Arf inactivation.
Adenocarcinoma spectrum with higher tumor multiplicity seen in Ink4a/Arf -/-than in p16 Ink4a-/-; few metastases seen in p16 Ink4a-/-. p16 (CDKN2A) somatic mutations identified in 5%-14% of lung adenocarcinoma. Adenocarcinoma spectrum; increased tumorigenesis with more inflammation and vascularity compared to K-ras G12D alone.
PTEN somatic mutations identified in 3% of human lung carcinoma.
K-ras LA2
Latent nonfunctional allele undergoes spontaneous recombination to activated K-ras G12D .
Adenocarcinoma spectrum; at advanced stages, rare metastases to LNs, kidney; thymic lymphomas, skin papillomas also seen.
K-ras somatic mutations identified in ~20%-30% of human lung adenocarcinomas.
K-ras FSF-G12D
Flp-dependent activation of K-ras G12D . Same histology as K-ras LSL-G12D . Can be combined with FRT-flanked p53 alleles.
Enables sequential mutation in combination with cre-lox system.
Activated K-ras transgenic lines
Transgenes expressing oncogenic K-ras in a cre-or dox-dependent manner.
Adenocarcinoma spectrum. Transgenic alleles may model K-ras amplification, which can occur in human disease. This system highlights the NE cells as the likely cell type of origin in most SCLC tumors and also provides tools to virally target cre expression to specific cell types in the lung. Over the past decade, significant progress has been made in developing mouse models of lung cancer that faithfully mimic the human disease. Lung cancer can be induced in mice by a variety of carcinogenesis protocols and constitutive germline mutations. We focus here on genetically engineered mouse models of lung cancer, rather than spontaneous mutant models or carcinogen-induced models. In particular, we highlight recent efforts to induce, in the pulmonary epithelium of adult mice, neoplastic mutations found in human cancer. These modeling efforts have relied predominantly on either transgene-mediated overexpression of an oncogene or recombinase-mediated manipulation of conditional alleles of oncogenes and tumor suppressors. These models have been used for basic studies of tumor progression and gene function in vivo, as well as for translational studies of targeted therapies and drug resistance mechanisms. The three most common types of human lung cancer and a summary of mouse modeling efforts are listed below.
EGFR activation

A D E N O C A R C I N O M A SMALL CELL LUNG CANCER
Adenocarcinoma
More genetically engineered models have been developed of adenocarcinoma than of any other lung cancer subtype. These models use several driver oncogenes that have been identified in human genomic studies. The earliest known precursor of human lung adenocarcinoma is atypical adenomatous hyperplasia (AAH), and many mouse models recapitulate the entire adenocarcinoma spectrum from AAH to invasive disease. Distant metastasis has been observed in several models, although this often requires the manipulation of more than one gene at the time of initiation.
Squamous Cell Carcinoma
Many human squamous cell carcinomas, particularly those that arise centrally, are thought to evolve from preinvasive lesions termed bronchial dysplasia, which then progress to in situ and invasive carcinoma. Some mouse adenocarcinoma models develop squamous histology. However, to date, there have been no reports of a genetically engineered mouse model of pure squamous cell carcinoma that recapitulates the natural progression of the human disease. Future modeling efforts will likely be aided by identifying candidate driver oncogenes and by elucidating the correct cells of origin for this disease.
Small Cell Lung Carcinoma
In humans, small cell lung carcinoma (SCLC) is an aggressive neuroendocrine neoplasm that has usually metastasized by the time of diagnosis. In the mouse, SCLC is initiated by deletion of two tumor suppressors (Rb and p53) that are usually downregulated, mutated or deleted in human SCLC. Deletion of these two genes produces a model that recapitulates the spectrum of human SCLC. The long latency of this model (macroscopic tumors are typically found 6-9 months after initiation) suggests that additional mutations are likely required for invasion and metastasis.
Abbreviations Dox, doxycycline; FSF, FRT-Stop-FRT; GEMM, genetically engineered mouse model; LNs, lymph nodes; LSL, Lox-Stop-Lox; NE, neuroendocrine; SCC, squamous cell carcinoma.
